Metabolic changes by niacin

JRCT ID: jRCT1040240146

Registered date:16/12/2024

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Hematologic malignancies and chronic inflammatory diseases
• Date of first enrollment: 16/12/2024
• Target sample size: 60
• Study type: Interventional
• Intervention(s): Nicotinamide

Outcome(s)

• Primary Outcome: Chenge in blood metabolite levels after taking supplement
• Secondary Outcome: Chenge in urinary metabolite levels after taking supplement

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

Patients with hematologic malignancies or chronic inflammatory diseases receiving medical care at Kanazawa Medical University Hospital

1) Patients with hematologic malignancies
Aged 18 years or older, regardless of gender.
Hematologic malignancies include patients diagnosed with acute or chronic leukemia, myelodysplastic syndromes, malignant lymphoma, or multiple myeloma.
Individuals who have provided written consent based on their own free will after sufficient informed consent regarding participation in this study.

2) Patients with chronic inflammatory diseases
Aged 18 years or older, regardless of gender.
Chronic inflammatory diseases include patients diagnosed with collagen diseases such as rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, systemic sclerosis, polymyositis/dermatomyositis, and mixed connective tissue disease.
Individuals who have provided written consent based on their own free will after sufficient informed consent regarding participation in this study.

Exclude criteria

1) Individuals who are pregnant, breastfeeding, or may become pregnant
2) Individuals taking medications or consuming various foods, including supplements, that contain nicotinamide, nicotinic acid, or NMN
3) Individuals with a history of hypersensitivity to medications or various foods, including supplements, containing nicotinamide, nicotinic acid, or NMN
4) Patients with severe organ failure (e.g., significant impairment of liver, kidney, or cardiac function)
5) Cases where individuals are unable to ingest supplements due to consciousness disorders or swallowing difficulties
6) Other cases deemed unsuitable as research subjects by the principal investigator or co-investigators for any reason

Related Information

• Primary Sponsor: Hirao Atsushi